Literature DB >> 15150087

Endogenous galectin-3 determines the routing of CD95 apoptotic signaling pathways.

Tomoharu Fukumori1, Yukinori Takenaka, Natsuo Oka, Tadashi Yoshii, Victor Hogan, Hidenori Inohara, Hiro-Omi Kanayama, Hyeong-Reh Choi Kim, Avraham Raz.   

Abstract

Studies of CD95 (APO-1/Fas), a member of the death receptor family, have revealed that it is involved in two primary CD95 apoptotic signaling pathways, one regulated by the large amount of active caspase-8 (type I) formed at the death-inducing signaling complex and the other by the apoptogenic activity of mitochondria (type II). To date, it is still unclear which pathway will be activated in response to an apoptotic insult. Here, we demonstrate that the antiapoptotic molecule galectin-3, which contains the four amino acid-anti-death-motif (NWGR) conserved in the BH1 domain of the Bcl-2 member proteins, is expressed only in type I cells. Transfection of galectin-3 cDNA into galectin-3 null cells (type II) resulted converting them to type I apoptotic phenotype. In addition, we show that galectin-3 is complexed with CD95 in vivo identifying galectin-3 as a novel CD95-binding partner that determines which of the CD95 apoptotic signaling pathways the cell will select.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15150087     DOI: 10.1158/0008-5472.CAN-04-0336

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  34 in total

Review 1.  The coming of age of galectins as immunomodulatory agents: impact of these carbohydrate binding proteins in T cell physiology and chronic inflammatory disorders.

Authors:  J M Ilarregui; G A Bianco; M A Toscano; G A Rabinovich
Journal:  Ann Rheum Dis       Date:  2005-11       Impact factor: 19.103

2.  A cell-based high-throughput screen to identify synergistic TRAIL sensitizers.

Authors:  Nancy Lynn Booth; Thomas J Sayers; Alan D Brooks; Cheryl L Thomas; Kristen Jacobsen; Ekaterina I Goncharova; James B McMahon; Curtis J Henrich
Journal:  Cancer Immunol Immunother       Date:  2008-12-17       Impact factor: 6.968

Review 3.  Nuclear transport of galectin-3 and its therapeutic implications.

Authors:  Tatsuyoshi Funasaka; Avraham Raz; Pratima Nangia-Makker
Journal:  Semin Cancer Biol       Date:  2014-03-19       Impact factor: 15.707

Review 4.  Evolving mechanistic insights into galectin functions.

Authors:  Connie M Arthur; Marcelo Dias Baruffi; Richard D Cummings; Sean R Stowell
Journal:  Methods Mol Biol       Date:  2015

Review 5.  Diagnostic utility of galectin-3 in thyroid cancer.

Authors:  Connie G Chiu; Scott S Strugnell; Obi L Griffith; Steven J M Jones; Allen M Gown; Blair Walker; Ivan R Nabi; Sam M Wiseman
Journal:  Am J Pathol       Date:  2010-04-02       Impact factor: 4.307

Review 6.  Protein glycosylation in cancer.

Authors:  Sean R Stowell; Tongzhong Ju; Richard D Cummings
Journal:  Annu Rev Pathol       Date:  2015       Impact factor: 23.472

7.  Racial disparity in breast cancer and functional germ line mutation in galectin-3 (rs4644): a pilot study.

Authors:  Vitaly Balan; Pratima Nangia-Makker; Ann G Schwartz; Young Suk Jung; Larry Tait; Victor Hogan; Tirza Raz; Yi Wang; Zeng Quan Yang; Gen Sheng Wu; Yongjun Guo; Huixiang Li; Judith Abrams; Fergus J Couch; Wilma L Lingle; Ricardo V Lloyd; Stephen P Ethier; Michael A Tainsky; Avraham Raz
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

8.  Galectin-3: a potential target for cancer prevention.

Authors:  Hafiz Ahmed; Prasun Guha; Engin Kaptan; Gargi Bandyopadhyaya
Journal:  Trends Carbohydr Res       Date:  2011

9.  Sialylation of beta1 integrins blocks cell adhesion to galectin-3 and protects cells against galectin-3-induced apoptosis.

Authors:  Ya Zhuo; Roger Chammas; Susan L Bellis
Journal:  J Biol Chem       Date:  2008-08-08       Impact factor: 5.157

Review 10.  Glycobiology of cell death: when glycans and lectins govern cell fate.

Authors:  R G Lichtenstein; G A Rabinovich
Journal:  Cell Death Differ       Date:  2013-05-24       Impact factor: 15.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.